CY1112674T1 - Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης - Google Patents

Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης

Info

Publication number
CY1112674T1
CY1112674T1 CY20121100133T CY121100133T CY1112674T1 CY 1112674 T1 CY1112674 T1 CY 1112674T1 CY 20121100133 T CY20121100133 T CY 20121100133T CY 121100133 T CY121100133 T CY 121100133T CY 1112674 T1 CY1112674 T1 CY 1112674T1
Authority
CY
Cyprus
Prior art keywords
combination
insulin secretion
triazine derivatives
inducers
secretion inducers
Prior art date
Application number
CY20121100133T
Other languages
English (en)
Inventor
Gérard Moinet
Daniel Cravo
Didier Mesangeau
Original Assignee
Poxel Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel Sas filed Critical Poxel Sas
Publication of CY1112674T1 publication Critical patent/CY1112674T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Η παρούσα δήλωση αφορά σε νέους συνδυασμούς ενός παραγώγου τριαζίνης και ενός διεγερτικού παράγοντα της έκκρισης ινσουλίνης.
CY20121100133T 2006-01-13 2012-02-08 Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης CY1112674T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP06829703A EP1971339B1 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators

Publications (1)

Publication Number Publication Date
CY1112674T1 true CY1112674T1 (el) 2016-02-10

Family

ID=36648317

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100133T CY1112674T1 (el) 2006-01-13 2012-02-08 Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης

Country Status (21)

Country Link
US (1) US8227465B2 (el)
EP (1) EP1971339B1 (el)
JP (1) JP5702911B2 (el)
KR (1) KR20080091366A (el)
CN (1) CN101355949A (el)
AR (1) AR059030A1 (el)
AT (1) ATE540682T1 (el)
AU (1) AU2006334731B2 (el)
BR (1) BRPI0620923A2 (el)
CA (1) CA2636837C (el)
CY (1) CY1112674T1 (el)
DK (1) DK1971339T3 (el)
EA (1) EA016649B1 (el)
ES (1) ES2378469T3 (el)
FR (1) FR2896157B1 (el)
IL (1) IL192596A (el)
PL (1) PL1971339T3 (el)
PT (1) PT1971339E (el)
SI (1) SI1971339T1 (el)
WO (1) WO2007079914A2 (el)
ZA (1) ZA200806938B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2355829T3 (pl) * 2008-12-12 2015-04-30 Poxel S A S Połączenie insuliny z pochodnymi triazyny i jego zastosowanie do leczenia cukrzycy
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
RU2550798C2 (ru) * 2011-05-12 2015-05-10 Василий Иосифович Зоря Способ стимуляции секреции инсулина
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
KR20200102982A (ko) 2017-10-02 2020-09-01 폭셀 보존된 박출률을 갖는 심부전의 치료 방법
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CN112218623A (zh) * 2018-06-14 2021-01-12 博希尔公司 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂
USD945167S1 (en) 2018-10-31 2022-03-08 Kimberly-Clark Worldwide, Inc. Paper sheet
KR20220113942A (ko) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 제조성 및 용출성이 우수한 소형 정제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CN1977842A (zh) * 2000-01-21 2007-06-13 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂和抗糖尿病药物的联合形式
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
ITFI20010126A1 (it) 2001-07-09 2003-01-09 Molteni & C Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide
MXPA04007183A (es) * 2002-01-25 2006-03-06 Silanes Sa De Cv Lab Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
EA200600356A1 (ru) * 2003-09-02 2006-08-25 Прозидион Лимитед Комбинированная терапия для гликемического контроля

Also Published As

Publication number Publication date
EA016649B1 (ru) 2012-06-29
AR059030A1 (es) 2008-03-12
BRPI0620923A2 (pt) 2011-11-29
WO2007079914A3 (en) 2007-09-07
JP5702911B2 (ja) 2015-04-15
ES2378469T3 (es) 2012-04-12
JP2009523139A (ja) 2009-06-18
CA2636837A1 (en) 2007-07-19
WO2007079914A2 (en) 2007-07-19
EP1971339B1 (en) 2012-01-11
PL1971339T3 (pl) 2012-04-30
DK1971339T3 (da) 2012-02-20
FR2896157B1 (fr) 2008-09-12
CN101355949A (zh) 2009-01-28
FR2896157A1 (fr) 2007-07-20
ATE540682T1 (de) 2012-01-15
SI1971339T1 (sl) 2012-07-31
US20100233255A1 (en) 2010-09-16
EP1971339A2 (en) 2008-09-24
AU2006334731B2 (en) 2012-06-21
AU2006334731A1 (en) 2007-07-19
KR20080091366A (ko) 2008-10-10
IL192596A0 (en) 2009-09-22
CA2636837C (en) 2013-12-10
EA200801665A1 (ru) 2008-12-30
US8227465B2 (en) 2012-07-24
ZA200806938B (en) 2010-02-24
IL192596A (en) 2015-07-30
PT1971339E (pt) 2012-02-20

Similar Documents

Publication Publication Date Title
CY1112674T1 (el) Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
CY1113188T1 (el) Τροποποιημενα fgf-21 πολυπεπτιδια και οι χρησεις τους
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CY1113435T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο
BRPI1010887A2 (pt) derivados de triazina e suas aplicações terapêuticas.
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина
CL2007002182S1 (es) Terminal.
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
ME01459B (me) Postupak za doziranje medikamenata
TW200740716A (en) Tetraphenylnaphthalene derivatives and organic light emitting diode using the same
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
NO20082118L (no) Heterocykliske CETP-inhibitorer
NO20082185L (no) Heterocykliske CETP-inhibitorer
CY1110857T1 (el) Καινοφανες παραγωγο αρυλαμιδινης, αλας αυτου και αντιμυκητιασικος παραγοντας που τα περιεχει αυτα
UA107068C2 (xx) Гербіцидна комбінація, що містить дифлуфенікан та інгібітор алс
ATE433975T1 (de) Als inos-inhibitoren geeignete imidazopyridinderivate
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии
CY1112716T1 (el) Συνδυαστικο φαρμακο το οποιο περιεχει προβουκολη και παραγωγο τετραζολυλαλκοξυ-διυδροκαρβοστυριλιου με αποτελεσματα καταστολεα υπεροξειδιου
DE112007003102A5 (de) Laserlichtquelle
ITMI20061609A1 (it) Formulazioni intrasinoviali di stanozololo
DE602005008653D1 (de) Pumpvorrichtung für einen optischen Laserverstärker